RSV mar­ket­ing bat­tle shap­ing up with GSK and Pfiz­er cam­paigns run­ning on TV, dig­i­tal chan­nels ahead of the vi­ral sea­son

The RSV vac­cine mar­ket­ing wars are heat­ing up. GSK be­gan its aware­ness ef­forts around res­pi­ra­to­ry syn­cy­tial virus vac­cines for old­er adults in the spring, but this week it added a brand­ed prod­uct cam­paign. And now Pfiz­er’s al­so in the mix with its own RSV aware­ness cam­paign, which be­gan ear­li­er this month.

GSK’s brand­ed Arexvy TV com­mer­cial, now out, touts “the first FDA ap­proved RSV vac­cine” along with an ar­ray of clin­i­cal facts about its use and ef­fec­tive­ness. Mean­while, Pfiz­er’s first aware­ness ef­fort de­buted at the be­gin­ning of the month with a 30-sec­ond TV com­mer­cial. The ad fea­tures a cast of ac­tive old­er peo­ple with “warn­ing la­bels.” The la­bels show up on a boc­ce ball, the top of a woman’s hat, on a menu and even on a tow­el at the gym as a voiceover warns that RSV is high­ly con­ta­gious and can be dan­ger­ous for peo­ple 60 and old­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER